Latest news with #Fortrea
Business Upturn
a day ago
- Business
- Business Upturn
Wolf Haldenstein Encourages Fortrea Holdings, Inc. (NASDAQ: FTRE) Investors with Losses to Secure Counsel Ahead of the August 1, 2025 Deadline
By GlobeNewswire Published on June 27, 2025, 20:10 IST NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP , a global investor rights law firm, reminds purchasers of Fortrea Holdings, Inc. (NASDAQ: FTRE) ('Fortrea') securities between July 3, 2023 and February 28, 2025 (the 'Class Period'), inclusive, of the important August 1, 2025 deadline to seek appointment as lead plaintiff in the securities class action lawsuit. Investors who purchased or otherwise acquired shares of Rocket should contact the Firm prior to the August 1, 2025 lead plaintiff motion deadline. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION CLASS PERIOD: July 3, 2023 and February 28, 2025 ALLEGATIONS: The filed complaint alleges that Fortrea misled investors by overstating projected revenue from Pre-Spin Projects, exaggerating expected cost savings from exiting transition service agreements, and inflating EBITDA targets for 2025. These misstatements, the suit claims, misrepresented the company's financial outlook and business model viability. When the truth was revealed, investors suffered losses. DEADLINE: August 1, 2025. Shareholders should contact Wolf Haldenstein as soon as possible Why Wolf Haldenstein Adler Freeman & Herz LLP ?: This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors. We encourage all investors who have been suffered losses or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP. Contact: Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Associated Press
a day ago
- Business
- Associated Press
Wolf Haldenstein Encourages Fortrea Holdings, Inc. (NASDAQ: FTRE) Investors with Losses to Secure Counsel Ahead of the August 1, 2025 Deadline
NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP , a global investor rights law firm, reminds purchasers of Fortrea Holdings, Inc. (NASDAQ: FTRE) ('Fortrea') securities between July 3, 2023 and February 28, 2025 (the 'Class Period'), inclusive, of the important August 1, 2025 deadline to seek appointment as lead plaintiff in the securities class action lawsuit. Investors who purchased or otherwise acquired shares of Rocket should contact the Firm prior to the August 1, 2025 lead plaintiff motion deadline. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION CLASS PERIOD: July 3, 2023 and February 28, 2025 ALLEGATIONS: The filed complaint alleges that Fortrea misled investors by overstating projected revenue from Pre-Spin Projects, exaggerating expected cost savings from exiting transition service agreements, and inflating EBITDA targets for 2025. These misstatements, the suit claims, misrepresented the company's financial outlook and business model viability. When the truth was revealed, investors suffered losses. DEADLINE: August 1, 2025. Shareholders should contact Wolf Haldenstein as soon as possible Why Wolf Haldenstein Adler Freeman & Herz LLP?: This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors. We encourage all investors who have been suffered losses or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP. Contact: Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Barnama
4 days ago
- Business
- Barnama
Fortrea, Emery Pharma Team Up On Rifampin Safety Testing For Clinical Trials
BUSINESS KUALA LUMPUR, June 25 (Bernama) -- Fortrea, a global contract research organisation (CRO), has announced a strategic collaboration with Emery Pharma to provide rapid impurity testing of rifampin used in drug-drug interaction (DDI) studies. In a statement, Fortrea said the partnership will enable testing for 1-methyl-4-nitrosopiperazine (MNP), a nitrosamine impurity, ensuring levels remain below the acceptable intake limit set by the United States Food and Drug Administration (FDA). Fortrea Chief Medical Officer and President of Clinical Pharmacology Services, Dr Oren Cohen said the partnership would help accelerate early-phase clinical trials by providing certified rifampin for use in DDI studies and enhance data quality. 'This collaboration reflects our shared commitment to smarter study design and greater participant safety,' he said. Meanwhile, Emery Pharma Chief Executive Officer, Dr Ron Najafi said the collaboration would contribute to safer and more efficient drug development, adding that the company specialises in solving complex analytical challenges in compliance with regulatory standards. Fortrea selected Emery Pharma based on its expertise in analytical and bioanalytical testing under current Good Manufacturing Practice (cGMP) and Good Laboratory Practice (GLP) standards. The new testing service is now available to Fortrea customers involved in clinical pharmacology trials, with study designs tailored to FDA requirements. Rifampin, a widely used antibiotic and a preferred agent in DDI studies due to its safety and tolerability, had previously come under scrutiny after the FDA found that MNP levels in tested batches exceeded acceptable limits. However, the agency revised its guidance in 2023, allowing the continued use of rifampin under updated thresholds.
Barnama
4 days ago
- Business
- Barnama
Fortrea & Emery Pharma Announce Strategic Collaboration To Deliver FDA Compliant Drug-drug-interaction Studies Using Rifampin
DURHAM, N.C., June 25 (Bernama) -- Fortrea (Nasdaq: FTRE) (the 'Company'), a leading global contract research organization (CRO), today announced a strategic collaboration with Emery Pharma, a leading analytical and bioanalytical CRO providing testing services under current Good Manufacturing Practice (cGMP) and Good Laboratory Practice (GLP), to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction (DDI) studies, to certify impurities are below the Acceptable Intake (AI) Limit set by U.S. Food and Drug Administration (FDA) guidelines. Fortrea has selected Emery Pharma due to its strong capabilities in analytical and bioanalytical testing in support of Fortrea's global clinical programs. Emery Pharma's expertise in this area supports Fortrea's ability to offer rifampin as an agent for inducing the CYP3A4 isoenzyme in DDI studies. The collaboration announced today allows sponsors to conduct DDI assessments using rifampin, which is frequently named as the preferred agent in these studies, due to its safety and tolerability profile.
Associated Press
4 days ago
- Business
- Associated Press
ROSEN, A LEADING LAW FIRM, Encourages Fortrea Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - June 24, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fortrea Holdings, Inc. (NASDAQ: FTRE) between July 3, 2023 and February 28, 2025, both dates inclusive (the 'Class Period'), of the important August 1, 2025 lead plaintiff deadline. SO WHAT: If you purchased Fortrea securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Fortrea class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 1, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to Fortrea's 2025 earnings; (2) Fortrea overstated the cost savings it would likely achieve by exiting the transition service agreements ('TSAs'); (3) as a result, Fortrea's previously announced EBITDA targets for 2025 were inflated; (4) accordingly, the viability of Fortrea's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (5) as a result, Fortrea's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Fortrea class action, go to call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit
